Currently out of the existing stock ratings of Michael Ulz, 167 are a BUY (65.75%), 82 are a HOLD (32.28%), 5 are a SELL (1.97%).

Michael Ulz

Work Performance Price Targets & Ratings Chart

Analyst Michael Ulz, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 48.95% that have a potential upside of 41.39% achieved within 202 days. Previously, Michael Ulz worked at BAIRD.

Michael Ulz’s has documented 489 price targets and ratings displayed on 55 stocks. The coverage is on Healthcare, Financial Services, Industrials sectors.

Most recent stock forecast was given on DYN, Dyne Therapeutics .

Wall Street Analyst Michael Ulz

Analyst best performing recommendations are on NRIX (NURIX THERAPEUTICS ).
The best stock recommendation documented was for IONS (IONIS PHARMACEUTICALS) at 11/2/2023. The price target of $45 was fulfilled within 1 day with a profit of $1.27 (2.9%) receiving and performance score of 29.04.

Average potential price target upside

of $128.03 (83.42%) on KPTI (KARYOPHARM THERAPEUTICS).
of $76.55 (75.05%) on ALVR (ALLOVIR ).
of $40.81 (68.95%) on LUMO (LUMOS PHARMA).

ALXN Alexion Pharmaceuticals AVRO AVROBIO BMRN Biomarin Pharmaceutical FOLD Amicus Therapeutics IOVA Iovance Biotherapeutics KPTI Karyopharm Therapeutics MRTX Mirati Ther NLNK NewLink Genetics CHRS Coherus BioSciences FATE Fate Therapeutics NRIX Nurix Therapeutics RARE Ultragenyx ALLK Allakos IGMS IGM Biosciences LUMO Lumos Pharma ISEE IVERIC bio MRSN Mersana Therapeutics BPMC Blueprint Medicines Corp YMAB Y mAbs Therapeutics AKRO Akero Therapeutics ALNY Alnylam Pharmaceuticals ALVR Allovir CABA Cabaletta Bio IONS Ionis Pharmaceuticals ORIC Oric Pharmaceuticals XLO Xilio Development JNCE Jounce Therapeutics FRLN Freeline Therapeutics Holdings Plc TSHA Taysha Gene Therapies VIR Vir Biotechnology ZNTL Zentalis Pharmaceuticals Llc ALPN Alpine Immune Sciences SLN Silence Therapeutics PLC ARWR Arrowhead Pharmaceuticals DYN Dyne Therapeutics MIRM Mirum Pharmaceuticals VKTX Viking Therapeutics GUTS Fractyl Health, Common Stock THRD Third Harmonic Bio APLS Apellis Pharmaceuticals ARGX argenx NV ADR AVEO AVEO Pharmaceuticals CNST Constellation Pharmaceuticals GNCA Genocea Biosciences HARP Harpoon Therapeutics IDRA Idera Pharmaceuticals PRTK Paratek Pharmaceuticals PRTO Proteon Therapeutics TARA Protara Therapeutics AKR Acadia Realty Trust ALL The Allstate KYTX Kyverna Therapeutics, Common Stock MACK Merrimack Pharmaceuticals THR AL Air Lease

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Hartaj Singh (OPPENHEIMER)

Buy Since 28-Jul-2017

$205

$22.5 (12.33%)

5 years 4 months 5 days ago
(05-May-2021)

3/5 (60%)

$35.09 (20.65%)

938

Geoffrey Porges (LEERINK)

Hold Since 03-May-2021

$173

$-9.5 (-5.21%)

$156

5 years 4 months 7 days ago
(03-May-2021)

17/29 (58.62%)

$2.73 (1.60%)

650

Martin Auster (RAYMOND JAMES)

Hold Since 04-Feb-2021

$190

$7.5 (4.11%)

$190

5 years 4 months 15 days ago
(26-Apr-2021)

11/14 (78.57%)

$23 (13.77%)

420

Phil Nadeau (TD COWEN)

Buy Since 06-Sep-2019

$175

$-7.5 (-4.11%)

$165

5 years 7 months 6 days ago
(04-Feb-2021)

3/3 (100%)

$19.41 (12.48%)

397

Christopher James

Buy Since 17-Jul-2017

$166

$-16.5 (-9.04%)

$175

5 years 7 months 6 days ago
(04-Feb-2021)

32/33 (96.97%)

$10.41 (6.69%)

867

Show more analysts

Please expand the browser size to see the chart

Which stock is Michael Ulz most bullish on?

Potential upside of $49.1 has been obtained for MIRM (MIRUM PHARMACEUTICALS)

Which stock is Michael Ulz most reserved on?

Potential downside of $1.21 has been obtained for KPTI (KARYOPHARM THERAPEUTICS)

What Year was the first public recommendation made by Michael Ulz?

On 2016